CLDX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
22.0K
+46.7%
15.0K
-87.6%
121.0K
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
22.0K
+46.7%
15.0K
-87.6%
121.0K
0
Operating Expenses
82.3M
+2.0%
80.6M
-4.5%
84.5M
-3.2%
87.3M
+18.6%
73.6M
R&D
67.4M
-0.2%
67.5M
-7.5%
73.0M
-3.1%
75.3M
+19.7%
62.9M
SG&A
14.8M
+13.3%
13.1M
+14.4%
11.4M
-4.1%
11.9M
+11.7%
10.7M
Operating Income
-82251000
-2.0%
-80623000
+4.5%
-84435000
+3.1%
-87153000
-18.4%
-73617000
EBITDA
-81089000
-1.7%
-79721000
+4.6%
-83581000
+3.2%
-86337000
-18.6%
-72793000
Net Income
-75557000
-2.8%
-73503000
+6.6%
-78685000
+3.2%
-81317000
-21.3%
-67044000
EPS (Basic)
$-0.96
-2.1%
$-0.94
+20.3%
$-1.18
+3.3%
$-1.22
-20.8%
$-1.01
EPS (Diluted)
$-0.96
-2.1%
$-0.94
+20.3%
$-1.18
+3.3%
$-1.22
-20.8%
$-1.01
Shares (Diluted)
78.5M
+0.9%
77.8M
+16.9%
66.6M
+0.1%
66.5M
+0.1%
66.4M
Celldex Therapeutics (CLDX) — Financials